BioHub

What BioHub does

Biohub is a nonprofit scientific research organization operating under the Chan Zuckerberg Initiative that combines frontier AI with frontier biology to accelerate the understanding, detection, prevention, and cure of disease. Established as part of CZI's philanthropic commitment — with $4 billion invested since 2016 and the majority of CZI's charitable resources now directed to Biohub — the organization develops AI systems to model biology, including virtual cell models and large biological datasets, supported by expanding compute infrastructure. In November 2025, CZI centralized all of its scientific teams under Biohub and acquired EvolutionaryScale, a life-sciences AI algorithms company, bringing frontier AI capability directly into the research organization. Biohub has produced peer-reviewed work, including a study in Science Translational Medicine on an amino acid cocktail co-formulation strategy that improved mRNA delivery and CRISPR gene editing efficiency by 5- to 20-fold in preclinical models, raising gene editing efficiency from a 20–30% baseline to 85–90% and survival in liver injury models from 33% to 100%.

The organization does not sell commercial products and has no disclosed pricing; its operating model is philanthropic grant funding from CZI, and its outputs are scientific research, datasets, AI models, and publications rather than licensed technology or services. Customers in the conventional sense do not exist — the organization serves the broader biomedical research community and, ultimately, patients, through its scientific mission. Geographic operating footprint was not explicitly disclosed in the source material, though the firm is headquartered within the CZI ecosystem associated with Mark Zuckerberg and Dr. Priscilla Chan. The competitive position rests on capital depth ($4B), in-house AI-for-biology capability via EvolutionaryScale, peer-reviewed research output, and the unique ability to align long-horizon scientific work under a single philanthropic mandate.

Name

BioHub

Legal name

BioHub

Website

https://bio-hub.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Biohub is a Chan Zuckerberg Initiative–funded nonprofit research organization that combines frontier AI with frontier biology to accelerate disease understanding and cure, having centralized CZI's scientific teams and acquired EvolutionaryScale in November 2025.

Ownership category

akta.pro rank

Product category

Biomedical Research

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industry

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

Keywords

• Biomedical research
• AI biology modeling
• Computational biology
• Disease research platforms
• Gene therapy delivery

Headquarters

HQ city

Fribourg

HQ country

Switzerland

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Core offering

BioHub is a nonprofit scientific research organization that combines frontier artificial intelligence with frontier biology to accelerate the understanding, detection, prevention, and cure of human diseases. It develops AI systems to model biology — including virtual cell models — and conducts research to improve therapeutic delivery mechanisms such as mRNA delivery and CRISPR gene editing. The organization operates research labs that integrate biological datasets, cell models, and computational approaches to address grand scientific challenges in biological discovery.

Product overview

BioHub is a scientific research organization that functions as a network of research labs aiming to combine biology and AI to advance healthcare. The organization develops AI systems to understand and model biology, focusing on accelerating disease detection, prevention, and cure. BioHub operates as a unified entity under the Chan Zuckerberg Initiative, consolidating scientific teams to leverage artificial intelligence for biomedical discovery. The platform develops virtual cell models and addresses grand scientific challenges through expanded compute capacity and biological datasets.

Differentiator

Problem solved

Functional benefit

Products and services

• BioHub Research Platform

Quantifiable outcome

• 5- to 20-fold improvement in mRNA delivery and CRISPR gene editing efficiency with amino acid cocktail co-formulation
• +2 more outcomes

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature1 record

Partnerships

One partnership is on record.

• EvolutionaryScalecoreTechnology or Integration · 1 November 2025The Chan Zuckerberg Initiative acquired EvolutionaryScale, a company developing AI algorithms for life sciences, as part of restructuring efforts to unify its scientific and research entities under Biohub. This acquisition brings frontier AI capabilities directly into Biohub's scientific research operations.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Google DeepMind: Applied AI research division of Alphabet behind AlphaFold and AlphaFold 3 — the canonical AI-for-biology effort. Operates at substantially greater scale and compute capacity than Biohub, with overlapping ambition to model biological systems computationally.
• Broad Institute of MIT and Harvard: Large nonprofit genomics and biomedical research institute. Comparable as a well-funded biomedical research organization applying large-scale biology and computational approaches to disease, although with a much broader portfolio than Biohub's AI-focused scope.
• Howard Hughes Medical Institute (Janelia Research Campus): Major biomedical research philanthropy with Janelia Research Campus focused on tool development and basic science. Comparable as a deep-pocketed nonprofit research organization pursuing ambitious life-science questions on a long time horizon.

Regional players

• Wellcome Sanger Institute: UK-based genomic and computational biology research institute funded by the Wellcome Trust. Comparable as a large-scale, philanthropically funded genomics and disease research organization, but UK-focused rather than US-based.

Direct peers

• Isomorphic Labs: Alphabet-founded commercial spinout using AI (rooted in DeepMind's AlphaFold) to accelerate drug discovery. Directly comparable mission of using frontier AI to model biology and develop therapeutics, though structured as a for-profit entity.
• Arc Institute: Nonprofit research organization co-founded with CZI that combines frontier AI with biology to understand and treat disease. Operates as a Palo Alto-based scientific research hub with overlapping mission, funding sources, and scientific leadership overlap with Biohub.

Emerging players

• Recursion Pharmaceuticals: Publicly traded AI-driven drug discovery company combining high-throughput biology with machine learning. Comparable mission of AI-for-biology drug discovery but commercial orientation, which contrasts with Biohub's nonprofit research posture.
• Insitro: AI-driven drug discovery company combining machine learning with biology and chemistry. Comparable in applying frontier AI/ML to model biology, though operates as a venture-backed commercial company with pharma partnerships rather than a research nonprofit.

Others

• Allen Institute for AI (AI2): Nonprofit AI research institute founded by the late Paul Allen. Comparable as a mission-driven, philanthropically funded AI research organization, though focused on general AI rather than biological applications — relevant for talent and model-development comparisons.
• Chan Zuckerberg Initiative (CZI): Parent philanthropic entity of Biohub founded by Mark Zuckerberg and Priscilla Chan. Relevant as the funding and strategic umbrella organization — without CZI, Biohub does not exist — and serves as a comparative case of large-scale health-philanthropy deployment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/biohub

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioHub